Optimal administration of fosaprepitant in patients with colon cancer

Optimal administration of fosaprepitant in patients with colon cancer - Administration of fosaprepitant to colon cancer patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010181

Enrollment

Registered

2013-03-06

Start date

2013-01-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon Cancer

Interventions

1.5mg/mL 0.6mg/mL

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with colon or rectal cancer 2) Age: 20 years old or older 3) Sex: Male or female 4) Patients with colon or rectal cancer undergoing chemotherapy including oxaliplatin or irinotecan* for the first time (naive patients) or those who have already received this therapy (non-naive patients) 5) Stage: Any stage, regardless of postoperative adjuvant chemotherapy or advanced or recurrent disease 6) Patients who give written informed consent to participate in the study * CPT-11(weekly, biweekly), Erbitax+CPT-11, XELOX, XELOX+ Avastin, IRIS

Exclusion criteria

Exclusion criteria: 1) Patients who previously developed serious or irreversible adverse effects at the administration site 2) Patients who were judged to be inappropriate as subjects by the study investigators

Design outcomes

Primary

Measure	Time frame
Pain at the injection site evaluated by NRS	—

Secondary

Measure	Time frame
Development site, time of development, duration of symptoms, reaction of injection site, and procedures to decrease symptoms	—

Countries

Japan

Contacts

Public Contactyuka aimono

Hitachi General Hospital clinical reserch center

0294-23-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026